

2024 Independent Medical Education Request for Proposal

Issue Date: April 3rd, 2024

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposal (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech’s scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech’s department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	<ul style="list-style-type: none">• U.S. based education provider• Registered account in gFRS• Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	<ul style="list-style-type: none">• Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 4 weeks to complete a full application. Please include "RFP" in the title your program	May 2, 2024
Step 2	After 2 weeks, respective Genentech Medical Education Managers will review and provide notification of final decisions via email	May 15, 2024

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available RFP Focus Area:

Focus	Opportunity
<p>Therapeutic Area: Oncology</p> <p>Disease: Follicular Lymphoma Diffuse Large B Cell Lymphoma</p> <p>Learning Audience: Emergency Department Physicians</p> <p>Support Available: Up to \$200,000</p> <p>Knowledge- and Competence-based Regional and Local Education <i>(Understanding & Addressing national or local gaps & emerging data)</i></p>	<p>During the last decade, the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like T-cell engaging bispecific antibodies and chimeric antigen receptor (CAR) T cells have shown efficacy in clinical trials and some of these agents have already received regulatory approval. However, along with growing experience in the clinical application of these potent immunotherapeutic agents comes the increasing awareness of their potentially serious or life-threatening adverse effects, most notably cytokine release syndrome (CRS).</p> <p>It is important for emergency room physicians to be able to recognize and manage oncologic emergencies like CRS to improve patient outcomes.</p> <p>Genentech is looking for independent medical education that is evidence-based, engaging, and designed to have a practical impact on the day-to-day clinical practices of emergency room physicians treating cancer patients. Emergency medical group partnerships for the educational program(s) are highly valued.</p> <p>References:</p> <ol style="list-style-type: none"> 1. Cobb DA, Lee DW. Cytokine Release Syndrome Biology and Management. <i>Cancer J.</i> 2021 Mar-Apr 01;27(2):119-125. doi: 10.1097/PPO.0000000000000515. PMID: 33750071. 2. Dubbs SB, Falat C, Rosenblatt L. Immune-based Therapies-What the Emergency Physician Needs to Know. <i>Emerg Med Clin North Am.</i> 2022 Feb;40(1):135-148. doi: 10.1016/j.emc.2021.08.011. Epub 2021 Oct 29. PMID: 34782084; PMCID: PMC9758283.